Related Experiment Videos
Intracerebral choriocarcinoma
W B Jones1, K M Wagner-Reiss, J L Lewis
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Abstract:
Nineteen patients with gestational trophoblastic disease (GTD) metastatic to the brain are reviewed. These patients constituted 9.0% of 210 [corrected] patients with GTD treated between November 1967 and December 1987. Four patients (21%) presented with primary neurological symptoms of GTD; four patients developed brain metastases during or after treatment with first drug(s) therapy; and 11 patients developed CNS metastases after resistance to initial chemotherapy. The initial chemotherapy in three of four patients who presented with brain metastases was with the combination of methotrexate, actinomycin D, and chlorambucil (MAC). Of the 15 patients who developed brain metastases after prior chemotherapy, 12 had received MAC at least once prior to the diagnosis of brain metastases, and in 5 patients, MAC was the first chemotherapy given after the diagnosis of brain metastases. All of the patients received whole-brain radiotherapy. Five of nineteen patients (26.3%) are living and well 4 to 15 years after the diagnosis of brain metastases. One of four patients (25%) who presented with brain metastases survived. These results suggest that MAC chemotherapy did not prevent the development of brain metastases in some of the patients and was less than optimal therapy in those whose brain tumor had become resistant to other cytotoxic agents.
Insights
Gestational trophoblastic disease (GTD) brain metastases occurred in 9% of patients. Methotrexate, actinomycin D, and chlorambucil (MAC) chemotherapy showed limited success in preventing or treating brain metastases, with a 26.3% survival rate.
Area of Science:
- Oncology
- Neurology
- Gynecology
Background:
- Gestational trophoblastic disease (GTD) can metastasize to the brain.
- Brain metastases represent a significant challenge in GTD management.
Purpose of the Study:
- To review outcomes of patients with GTD metastatic to the brain.
- To evaluate the role of methotrexate, actinomycin D, and chlorambucil (MAC) chemotherapy in these patients.
Main Methods:
- Retrospective review of 19 patients with GTD metastatic to the brain treated between 1967 and 1987.
- Analysis of chemotherapy regimens, including MAC, and whole-brain radiotherapy.
Main Results:
- Brain metastases occurred in 9.0% of GTD patients.
- 26.3% (5/19) of patients with brain metastases survived long-term.
- MAC chemotherapy did not consistently prevent brain metastases and was less effective in resistant cases.
Conclusions:
- Whole-brain radiotherapy was standard treatment.
- The efficacy of MAC chemotherapy in preventing or treating GTD brain metastases appears limited.
- Further research into optimal treatment strategies for GTD brain metastases is warranted.